---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-22-019342"
form_type: "8-K"
ticker: "MCAG"
cik: "0001859035"
company_name: "Mountain Crest Acquisition Corp. V"
filed_at: "2022-11-16T23:59:59+00:00"
generated_at: "2026-06-21T17:46:30.713597+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Mountain Crest V to combine with AUM Biosciences at ~$400M valuation; PIPE of $30M sought

## Summary
- Purchase price of ~$400M; AUM shareholders roll over 100% equity for ~84% of pro forma ownership.
- Targeted PIPE of $30M (not committed) to fund AUM balance sheet and transaction expenses.
- MCAG cash in trust of $69M; assumes 75% redemptions; $17.25M retained.
- AUM is a precision oncology company with pipeline in Phase 2 for AUM001 and AUM601.
- Expected close Q1 2023, subject to customary conditions and approvals.

## SEC filing metadata
- accession: 0001829126-22-019342
- form_type: 8-K
- ticker: MCAG
- cik: 0001859035
- company_name: Mountain Crest Acquisition Corp. V
- filed_at: 2022-11-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859035/000182912622019342/0001829126-22-019342-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859035/000182912622019342/mountaincrest5_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-22-019342
- JSON: https://secwatch.observer/filing/0001829126-22-019342.json
- Plain text: https://secwatch.observer/filing/0001829126-22-019342.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.